–   Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan

–   Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milestones of up to $175 million, transfer pricing, and commercial milestones

–   Ascendis Pharma is also eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product

COPENHAGEN, Denmark I November 29, 2023 I Ascendis Pharma A/S (Nasdaq: ASND) today announced that the company has entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan.

“We are pleased to partner with Teijin Pharma given their track record of navigating regulatory approval and commercialization of rare disease and endocrinology product candidates in Japan, and commitment to providing best-in-class therapies,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “We believe this collaboration is a major step in our journey to achieve global reach for our current Endocrinology Rare Disease portfolio by helping to address unmet medical needs of patients in Japan.”

“Ascendis has leveraged its innovative TransCon technology platform to create a suite of highly differentiated product candidates with best-in-class potential that complement our existing pharmaceutical portfolio,” said Akimoto Uchikawa, Teijin Limited’s President and Chief Executive Officer. “We expect this partnership will contribute a great deal to advance our healthcare business vision to address issues of patients, families and communities in need of more support followed by the introduction of pharmaceuticals in rare and intractable disease areas utilizing our business platform cultivated so far.”

Under the terms of the agreement, Ascendis will receive an upfront payment of $70 million, with additional development and regulatory milestones of up to $175 million, transfer pricing and commercial milestones. In addition, Ascendis Pharma is eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product.

About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Germany (Heidelberg and Munich) and the United States (Palo Alto and Redwood City, California, and Princeton, New Jersey). Please visit ascendispharma.com to learn more.

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people in 20 countries. Through “Human Chemistry, Human Solutions,” Teijin relentlessly strives to aims to be a company that supports the society of the future by protecting the global environment and addressing the needs of people and communities. Teijin posted consolidated sales of JPY 1,018.8 billion (USD 7.6 billion) and total assets of JPY 1,242.4 billion (USD 9.2 billion) in the fiscal year ending March 31, 2023. Please visit www.teijin.com to learn more.

SOURCE: Ascendis Pharma